Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
05/21/2013 | CA2349203C Dispersible phospholipid stabilized microparticles |
05/21/2013 | CA2305385C Human toll homologues |
05/21/2013 | CA2294865C Immunogenic lhrh compositions and methods relating thereto |
05/21/2013 | CA2279329C Protein fragment complementation assays to detect biomolecular interactions |
05/16/2013 | WO2013071262A1 Calcimimetics and methods for their use |
05/16/2013 | WO2013071231A1 Channelrhodopsins for optical control of cells |
05/16/2013 | WO2013071154A1 Cyclin a1-targeted t-cell immunotherapy for cancer |
05/16/2013 | WO2013071142A1 Biomarkers of response to proteasome inhibitors |
05/16/2013 | WO2013071049A1 Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
05/16/2013 | WO2013071030A1 Provasopressin antagonists and uses thereof |
05/16/2013 | WO2013070808A1 Peptide-based compounds as inhibitors of neurotransmitter secretion |
05/16/2013 | WO2013070741A1 Methods and materials for regulating natriuretic polypeptide function |
05/16/2013 | WO2013070734A1 Methods of cardiac repair |
05/16/2013 | WO2013070603A1 Compositions and methods for treatment of kidney diseases |
05/16/2013 | WO2013070529A1 Compositions and methods for inhibiting the interaction between cftr and cal |
05/16/2013 | WO2013070362A1 Compositions and methods for immune tolerance induction |
05/16/2013 | WO2013070048A1 Composition for preventing or treating ischaemic heart disease comprising, as an active ingredient, age-albumin synthesis or secretion inhibitor for mononuclear phagocyte system cells |
05/16/2013 | WO2013070011A1 Pharmaceutical composition for the prevention or treatment of neurological diseases comprising an ampa receptor endocytosis inhibitor |
05/16/2013 | WO2013070010A1 Novel composition for gene delivery |
05/16/2013 | WO2013068964A1 Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations |
05/16/2013 | WO2013068776A1 Combination of active ingredients for the treatment of acute kidney injury |
05/16/2013 | WO2013068701A1 Urotensin-ii for use in the treatment and/or prevention of diseases involving gastric motility |
05/16/2013 | WO2013068590A1 Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
05/16/2013 | WO2013068538A1 Process of purification of teicoplanin |
05/16/2013 | WO2013068517A1 Process of purification of teicoplanin |
05/16/2013 | WO2013068504A1 Apotransferrin for the treatment of brain stroke |
05/16/2013 | WO2013068476A1 Neurotoxins exhibiting shortened biological activity |
05/16/2013 | WO2013067770A1 Compositions and methods for treating traumatic brain injury |
05/16/2013 | WO2013067750A1 Polyclonal antibody immunologic mass spectrometry kit of liver cancer marker |
05/16/2013 | WO2013067639A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
05/16/2013 | WO2013044044A3 Methods of treating fatty liver disease with helminth-derived glycan-containing compounds |
05/16/2013 | WO2013040504A3 Srpx for treatment of cancer |
05/16/2013 | WO2013020108A3 Bile acid recycling inhibitors for treatment of pancreatitis |
05/16/2013 | WO2013015611A9 Composition for preventing damage to chondrocytes and regenerating same, including yeast hydrolysate as an active ingredient |
05/16/2013 | WO2012174534A3 Method of treating or ameliorating metabolic disorders using clec-2 |
05/16/2013 | WO2012068515A3 Compositions and methods for hair growth |
05/16/2013 | US20130125259 Rna interference mediating small rna molecules |
05/16/2013 | US20130123920 Device for tendon and ligament treatment |
05/16/2013 | US20130123201 Modulation of cytokine-induced chronic inflammatory responses |
05/16/2013 | US20130123200 Mammalian cell surface antigens; related reagents |
05/16/2013 | US20130123198 Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion |
05/16/2013 | US20130123195 Sustained action formulation of cyclosporin form 2 |
05/16/2013 | US20130123194 Autoclavable suspensions of cyclosporin a form 2 |
05/16/2013 | US20130123191 Methods of inhibiting photoreceptor apoptosis |
05/16/2013 | US20130123190 Methods for Treating Combined Radiation and Thermal Injury |
05/16/2013 | US20130123189 Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
05/16/2013 | US20130123186 Neuroprotection using nap-like and sal-like peptide mimetics |
05/16/2013 | US20130123185 Methods of treating and diagnosing acute chest syndrome |
05/16/2013 | US20130123184 Methods for increasing levels of human fetal hemoglobin |
05/16/2013 | US20130123183 Anti-tumor Fibrillar Human Serum Albumin Methods and Compositions |
05/16/2013 | US20130123177 Method of treating brain injury |
05/16/2013 | US20130123174 Neuritogenic peptides |
05/16/2013 | US20130123173 Creation of oxidation-resistant hdl mimetic peptides |
05/16/2013 | US20130123170 Growth Hormone Releasing Peptides |
05/16/2013 | US20130123168 Humanin and humanin-analogues for the management of atherosclerosis |
05/16/2013 | US20130123167 Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food |
05/16/2013 | US20130123122 Secreted proteins and uses thereof |
05/16/2013 | US20130122086 Method for treating celiac disease |
05/16/2013 | US20130122083 Dna vaccines encoding heat shock proteins |
05/16/2013 | US20130122082 Methods And Compositions For The Treatment And Prevention Of Aging-Associated Conditions |
05/16/2013 | US20130122076 Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease |
05/16/2013 | US20130122075 Encapsulated transfer factor compositions and methods of use |
05/16/2013 | US20130122066 Drug delivery devices and growth factor formulations for accelerated wound healing |
05/16/2013 | US20130122059 Suspensions of cyclosporin a form 2 |
05/16/2013 | US20130122053 Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
05/16/2013 | US20130122050 Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide |
05/16/2013 | US20130122046 Regulatory factor of foxp3 and regulatory t cells and use thereof |
05/16/2013 | US20130122031 Hmgb1-derived peptides enhance immune response to antigens |
05/16/2013 | US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
05/16/2013 | US20130122017 Osteoprotegerin in Neuroprotection |
05/16/2013 | US20130122013 Anti-ferroportin 1 monoclonal antibodies and uses thereof |
05/16/2013 | US20130122011 Multiple-variable dose regimen for treating TNFa-related disorders |
05/16/2013 | US20130121986 Nitrogenated derivatives of pancratistatin |
05/16/2013 | US20130121985 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
05/16/2013 | US20130121984 Biomarkers for sanfilippo syndrome and uses thereof |
05/16/2013 | US20130121982 Antidote to the bite of venomous snakes |
05/16/2013 | US20130121974 Methods of making enhanced, autologous fat grafts |
05/16/2013 | US20130121965 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
05/16/2013 | US20130121964 Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
05/16/2013 | US20130121956 Composition for Enhancing Bone Formation |
05/16/2013 | CA2855358A1 Cyclin a1-targeted t-cell immunotherapy for cancer |
05/16/2013 | CA2855356A1 Biomarkers of response to proteasome inhibitors |
05/16/2013 | CA2855173A1 Neurotoxins exhibiting shortened biological activity |
05/16/2013 | CA2855155A1 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
05/16/2013 | CA2854949A1 Apotransferrin for the treatment of brain stroke |
05/16/2013 | CA2854911A1 Calcimimetics and methods for their use |
05/16/2013 | CA2854563A1 Provasopressin antagonists and uses thereof |
05/16/2013 | CA2854467A1 Antagonists for abnormal vasopressin v2 receptor and uses thereof |
05/16/2013 | CA2854372A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
05/16/2013 | CA2840900A1 Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclearphagocyte system cells as active ingredient |
05/15/2013 | EP2592155A2 EGFR mutations |
05/15/2013 | EP2592090A1 Process of purification of teicoplanin |
05/15/2013 | EP2592089A1 Process of purification of teicoplanin |
05/15/2013 | EP2592088A1 Cyclic peptide compound or pharmacologically acceptable salt thereof and method for producing same |
05/15/2013 | EP2591806A1 Medicinal composition |
05/15/2013 | EP2591797A1 Regulatory factor of foxp3 and regulatory t cells and use thereof |
05/15/2013 | EP2591796A1 Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
05/15/2013 | EP2591795A1 RNA targeting compounds and methods for making and using same |
05/15/2013 | EP2591794A1 MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
05/15/2013 | EP2591793A2 Treatment of autoimmune disease |